Skip to content
2000
Volume 26, Issue 2
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

The p53 protein, renowned as the “anti-cancer protein,” plays a critical role in regulating the cell cycle, inducing apoptosis, and repairing DNA. Its dysregulation often leads to genomic instability and tumorigenesis. MDM2, a key negative feedback regulator of p53, inhibits both the transcriptional activity and stability of p53, thereby suppressing the anti-cancer effect of p53. With the resolution of the co-crystal structure of the MDM2-p53 complex, using small molecule inhibitors to block their interaction has emerged as a promising cancer treatment strategy. These inhibitors can remove the negative regulation of MDM2 on p53 and allow p53 to function as a “tumor suppressor protein”. Over recent decades, researchers have designed and synthesized small-molecule inhibitors with diverse structures, showing notable anti-cancer efficacy in preclinical studies. Although several inhibitors have entered clinical trials, none have yet been approved. This review comprehensively summarizes the recent advancements in small-molecule inhibitors of MDM2-p53 protein-protein interaction (PPI) according to different types of structural scaffolds, primarily focusing on imidazolines, spirooxindoles, pyrrolidines, pyrrolones, piperidones, purine carboxylic acid derivatives, isoquinolines, pyrazolopyrolidinone analogs, imidazothiazoles, quinolones, and spiroindolines. Additionally, this review focuses on their design, synthesis, and biological evaluation and highlights the structure-activity relationships and ongoing efforts. Despite the progress made, challenges remain. Researchers are exploring strategies to overcome these obstacles in promoting the research on drugs targeting MDM2-p53 PPI with stronger affinity, higher permeability, and a more significant effect.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206358340250121060830
2025-02-27
2026-02-28

  • From This Site

    /content/journals/acamc/10.2174/0118715206358340250121060830
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SungH. FerlayJ. SiegelR.L. LaversanneM. SoerjomataramI. JemalA. BrayF. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.202171320924910.3322/caac.21660 33538338
     [Google Scholar]
  2. KangZ. LiS. LiY. SongJ. PengY. ChenY. Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: An updated review (from 2022 to 2024).Chin. Chem. Lett.202411044710.1016/j.cclet.2024.110447
     [Google Scholar]
  3. HassinO. OrenM. Drugging p53 in cancer: One protein, many targets.Nat. Rev. Drug Discov.202322212714410.1038/s41573‑022‑00571‑8 36216888
     [Google Scholar]
  4. PunekarS.R. VelchetiV. NeelB.G. WongK.K. The current state of the art and future trends in RAS-targeted cancer therapies.Nat. Rev. Clin. Oncol.2022191063765510.1038/s41571‑022‑00671‑9 36028717
     [Google Scholar]
  5. OlivierM. HussainS.P. Caron de FromentelC. HainautP. HarrisC.C. TP53 mutation spectra and load: A tool for generating hypotheses on the etiology of cancer. IARC Sci. Publ.,2004157247270 15055300
     [Google Scholar]
  6. LevineA.J. p53, the cellular gatekeeper for growth and division.Cell199788332333110.1016/S0092‑8674(00)81871‑1 9039259
     [Google Scholar]
  7. HainautP. HollsteinM. p53 and human cancer: The first ten thousand mutations.Adv. Cancer Res.1999778113710.1016/S0065‑230X(08)60785‑X 10549356
     [Google Scholar]
  8. Cahilly-SnyderL. Yang-FengT. FranckeU. GeorgeD.L. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line.Somat. Cell Mol. Genet.198713323524410.1007/BF01535205 3474784
     [Google Scholar]
  9. TraweekR.S. CopeB.M. RolandC.L. KeungE.Z. NassifE.F. ErstadD.J. Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma.Front. Oncol.202212100695910.3389/fonc.2022.1006959 36439412
     [Google Scholar]
  10. CarrM.I. JonesS.N. Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis.Transl. Cancer Res.20165670772410.21037/tcr.2016.11.75 28690977
     [Google Scholar]
  11. ToufektchanE. ToledoF. The guardian of the genome revisited: P53 downregulates genes required for telomere maintenance, DNA repair, and centromere structure.Cancers (Basel)201810513510.3390/cancers10050135 29734785
     [Google Scholar]
  12. KanapathipillaiM. Treating p53 mutant aggregation-associated cancer.Cancers (Basel)201810615410.3390/cancers10060154 29789497
     [Google Scholar]
  13. XuZ. WuW. YanH. HuY. HeQ. LuoP. Regulation of p53 stability as a therapeutic strategy for cancer.Biochem. Pharmacol.202118511440710.1016/j.bcp.2021.114407 33421376
     [Google Scholar]
  14. NishikawaS. IwakumaT. Drugs targeting p53 mutations with fda approval and in clinical trials.Cancers (Basel)202315242910.3390/cancers15020429 36672377
     [Google Scholar]
  15. NagS. ZhangX. SrivenugopalK.S. WangM.H. WangW. ZhangR. Targeting MDM2-p53 interaction for cancer therapy: Are we there yet?Curr. Med. Chem.201421555357410.2174/09298673113206660325 24180275
     [Google Scholar]
  16. HanazonoK. NatsugoeS. SteinH. AikouT. HoeflerH. SiewertJ. Distribution of p53 mutations in esophageal and gastric carcinomas and the relationship with p53 expression.Oncol. Rep.200615482182410.3892/or.15.4.821 16525665
     [Google Scholar]
  17. MomandJ. WuH.H. DasguptaG. MDM2 — master regulator of the p53 tumor suppressor protein.Gene20002421-2152910.1016/S0378‑1119(99)00487‑4 10721693
     [Google Scholar]
  18. ZhaoY. YuH. HuW. The regulation of MDM2 oncogene and its impact on human cancers.Acta Biochim. Biophys. Sin. (Shanghai)201446318018910.1093/abbs/gmt147 24389645
     [Google Scholar]
  19. MichaelD. OrenM. The p53–Mdm2 module and the ubiquitin system.Semin. Cancer Biol.2003131495810.1016/S1044‑579X(02)00099‑8 12507556
     [Google Scholar]
  20. HauptY. MayaR. KazazA. OrenM. Mdm2 promotes the rapid degradation of p53.Nature1997387663029629910.1038/387296a0 9153395
     [Google Scholar]
  21. LevineA.J. p53: 800 million years of evolution and 40 years of discovery.Nat. Rev. Cancer202020847148010.1038/s41568‑020‑0262‑1 32404993
     [Google Scholar]
  22. FreedmanD.A. WuL. LevineA.J. Functions of the MDM2 oncoprotein.Cell. Mol. Life Sci.19995519610710.1007/s000180050273 10065155
     [Google Scholar]
  23. KussieP.H. GorinaS. MarechalV. ElenbaasB. MoreauJ. LevineA.J. PavletichN.P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.Science1996274528994895310.1126/science.274.5289.948 8875929
     [Google Scholar]
  24. WuX. BayleJ.H. OlsonD. LevineA.J. The p53-mdm-2 autoregulatory feedback loop.Genes Dev.199377a1126113210.1101/gad.7.7a.1126 8319905
     [Google Scholar]
  25. SubhasreeN. JiangjiangQ. KalkunteS. MinghaiW. RuiwenZ. The MDM2-p53 pathway revisited.J. Biomed. Res.201327425427110.7555/JBR.27.20130030 23885265
     [Google Scholar]
  26. LiuY. WangX. WangG. YangY. YuanY. OuyangL. The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.Eur. J. Med. Chem.20191769210410.1016/j.ejmech.2019.05.018 31100649
     [Google Scholar]
  27. RusieckiR. WitkowskiJ. Jaszczewska-AdamczakJ. Jaszczewska-Adamczak, J. Mdm2-p53 interaction inhibitors: The current state-of-art and updated patent review (2010-present).Recent Patents Anticancer Drug Discov.202014432436910.2174/1574892814666191022163540 31642413
     [Google Scholar]
  28. VassilevL.T. VuB.T. GravesB. CarvajalD. PodlaskiF. FilipovicZ. KongN. KammlottU. LukacsC. KleinC. FotouhiN. LiuE.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.Science2004303565984484810.1126/science.1092472 14704432
     [Google Scholar]
  29. HarrisC.C. Protein–protein interactions for cancer therapy.Proc. Natl. Acad. Sci. USA200610361659166010.1073/pnas.0510948103 16452164
     [Google Scholar]
  30. ZhaoC.Y. GrinkevichV. NikulenkovF. BaoW. SelivanovaG. Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA.Cell Cycle2010991847185510.4161/cc.9.9.11545 20436301
     [Google Scholar]
  31. SriramanA. RadovanovicM. WienkenM. NajafovaZ. LiY. DobbelsteinM. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.Oncotarget2016722316233163810.18632/oncotarget.9302 27183917
     [Google Scholar]
  32. HuC. LiX. WangW. ZhangL. TaoL. DongX. ShengR. YangB. HuY. Design, synthesis, and biological evaluation of imidazoline derivatives as p53–MDM2 binding inhibitors.Bioorg. Med. Chem.201119185454546110.1016/j.bmc.2011.07.050 21855354
     [Google Scholar]
  33. VuB. WovkulichP. PizzolatoG. LoveyA. DingQ. JiangN. LiuJ.J. ZhaoC. GlennK. WenY. TovarC. PackmanK. VassilevL. GravesB. Discovery of rg7112: A small-molecule mdm2 inhibitor in clinical development.ACS Med. Chem. Lett.20134546646910.1021/ml4000657 24900694
     [Google Scholar]
  34. TovarC. GravesB. PackmanK. FilipovicZ. XiaB.H.M. TardellC. GarridoR. LeeE. KolinskyK. ToK-H. LinnM. PodlaskiF. WovkulichP. VuB. VassilevL.T. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.Cancer Res.20137382587259710.1158/0008‑5472.CAN‑12‑2807 23400593
     [Google Scholar]
  35. PatnaikA. TolcherA. BeeramM. NemunaitisJ. WeissG.J. BhallaK. AgrawalM. NicholsG. MiddletonS. BeryozkinaA. SarapaN. PeckR. ZhiJ. Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors.Cancer Chemother. Pharmacol.201576358759510.1007/s00280‑015‑2830‑8 26210682
     [Google Scholar]
  36. AndreeffM. KellyK.R. YeeK. AssoulineS. StrairR. PopplewellL. BowenD. MartinelliG. DrummondM.W. VyasP. KirschbaumM. IyerS.P. RuvoloV. GonzálezG.M.N. HuangX. ChenG. GravesB. BlotnerS. BridgeP. JukofskyL. MiddletonS. RecknerM. RuegerR. ZhiJ. NicholsG. KojimaK. Results of the phase i trial of rg7112, a small-molecule mdm2 antagonist in leukemia.Clin. Cancer Res.201622486887610.1158/1078‑0432.CCR‑15‑0481 26459177
     [Google Scholar]
  37. Ray-CoquardI. BlayJ.Y. ItalianoA. Le CesneA. PenelN. ZhiJ. HeilF. RuegerR. GravesB. DingM. GehoD. MiddletonS.A. VassilevL.T. NicholsG.L. BuiB.N. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: An exploratory proof-of-mechanism study.Lancet Oncol.201213111133114010.1016/S1470‑2045(12)70474‑6 23084521
     [Google Scholar]
  38. NietzoldF. RubnerS. LabuzekB. GolikP. SurmiakE. del CorteX. KitelR. ProtzelC. Reppich-SacherR. StichelJ. Magiera-MularzK. HolakT.A. BergT. Nutlin-3a-aa: Improving the bioactivity of a p53/mdm2 interaction inhibitor by introducing a solvent-exposed methylene group.ChemBioChem2023246e20230000610.1002/cbic.202300006 36602436
     [Google Scholar]
  39. DingK. LuY. Nikolovska-ColeskaZ. QiuS. DingY. GaoW. StuckeyJ. KrajewskiK. RollerP.P. TomitaY. ParrishD.A. DeschampsJ.R. WangS. Structure-based design of potent non-peptide MDM2 inhibitors.J. Am. Chem. Soc.200512729101301013110.1021/ja051147z 16028899
     [Google Scholar]
  40. DingK. LuY. Nikolovska-ColeskaZ. WangG. QiuS. ShangaryS. GaoW. QinD. StuckeyJ. KrajewskiK. RollerP.P. WangS. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.J. Med. Chem.200649123432343510.1021/jm051122a 16759082
     [Google Scholar]
  41. LinJ. ChenJ. ElenbaasB. LevineA.J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.Genes Dev.19948101235124610.1101/gad.8.10.1235 7926727
     [Google Scholar]
  42. PicksleyS.M. VojtesekB. SparksA. LaneD.P. Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides.Oncogene19949925232529 8058315
     [Google Scholar]
  43. YuS. QinD. ShangaryS. ChenJ. WangG. DingK. McEachernD. QiuS. Nikolovska-ColeskaZ. MillerR. KangS. YangD. WangS. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.J. Med. Chem.200952247970797310.1021/jm901400z 19928922
     [Google Scholar]
  44. CannerJ.A. SoboM. BallS. HutzenB. DeAngelisS. WillisW. StudebakerA.W. DingK. WangS. YangD. LinJ. MI-63: A novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.Br. J. Cancer2009101577478110.1038/sj.bjc.6605199 19707204
     [Google Scholar]
  45. ZouP. ZhengN. YuY. YuS. SunW. McEachemD. YangY. YuL.X. WangS. SunD. Preclinical pharmacokinetics of MI-219, a novel human double minute 2 (HDM2) inhibitor and prediction of human pharmacokinetics.J. Pharm. Pharm. Sci.201215226528010.18433/J34S4N 22579006
     [Google Scholar]
  46. WangS. SunW. ZhaoY. McEachernD. MeauxI. BarrièreC. StuckeyJ.A. MeagherJ.L. BaiL. LiuL. Hoffman-LucaC.G. LuJ. ShangaryS. YuS. BernardD. AguilarA. Dos-SantosO. BesretL. GuerifS. PannierP. Gorge-BernatD. DebusscheL. SAR405838: An optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.Cancer Res.201474205855586510.1158/0008‑5472.CAN‑14‑0799 25145672
     [Google Scholar]
  47. BillK.L.J. GarnettJ. MeauxI. MaX. CreightonC.J. BolshakovS. BarriereC. DebusscheL. LazarA.J. PrudnerB.C. CasadeiL. BraggioD. LopezG. ZewduA. BidH. LevD. PollockR.E. Sar405838: A novel and potent inhibitor of the mdm2:P53 axis for the treatment of dedifferentiated liposarcoma.Clin. Cancer Res.20162251150116010.1158/1078‑0432.CCR‑15‑1522 26475335
     [Google Scholar]
  48. de JongeM. de WegerV.A. DicksonM.A. LangenbergM. Le CesneA. WagnerA.J. HsuK. ZhengW. MacéS. TuffalG. ThomasK. SchellensJ.H.M. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.Eur. J. Cancer20177614415110.1016/j.ejca.2017.02.005 28324749
     [Google Scholar]
  49. LuJ. McEachernD. LiS. EllisM.J. WangS. Reactivation of p53 by mdm2 inhibitor mi-77301 for the treatment of endocrine-resistant breast cancer.Mol. Cancer Ther.201615122887289310.1158/1535‑7163.MCT‑16‑0028 27765850
     [Google Scholar]
  50. ZhaoY. LiuL. SunW. LuJ. McEachernD. LiX. YuS. BernardD. OchsenbeinP. FereyV. CarryJ.C. DeschampsJ.R. SunD. WangS. Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors.J. Am. Chem. Soc.2013135197223723410.1021/ja3125417 23641733
     [Google Scholar]
  51. AguilarA. SunW. LiuL. LuJ. McEachernD. BernardD. DeschampsJ.R. WangS. Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles.J. Med. Chem.20145724104861049810.1021/jm501541j 25496041
     [Google Scholar]
  52. AguilarA. LuJ. LiuL. DuD. BernardD. McEachernD. PrzybranowskiS. LiX. LuoR. WenB. SunD. WangH. WenJ. WangG. ZhaiY. GuoM. YangD. WangS. Discovery of 4-((3′ R, 4′ S, 5′ R)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A potent and orally active Murine Double Minute 2 (MDM2) inhibitor in clinical development.J. Med. Chem.20176072819283910.1021/acs.jmedchem.6b01665 28339198
     [Google Scholar]
  53. ChenH. LuoD. ZhangL. LinX. LuoQ. YiH. WangJ. YanX. LiB. ChenY. LiuX. ZhangH. LiuS. QiuM. YangD. JiangN. Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells.Oncotarget2017826430084302210.18632/oncotarget.17398 28498808
     [Google Scholar]
  54. ZhaiY. TangQ. FangD.D. DengJ. ZhangK. WangQ. YinY. FuC. XueS.L. LiN. ZhouF. YangD. Lisaftoclax in combination with alrizomadlin overcomes venetoclax resistance in acute myeloid leukemia and acute lymphoblastic leukemia: Preclinical studies.Clin. Cancer Res.202329118319610.1158/1078‑0432.CCR‑22‑0978 36240005
     [Google Scholar]
  55. GollnerA. RudolphD. ArnhofH. BauerM. BlakeS.M. BoehmeltG. CockroftX.L. DahmannG. EttmayerP. GerstbergerT. Karolyi-OezguerJ. KesslerD. KofinkC. RamharterJ. RinnenthalJ. SavchenkoA. SchnitzerR. WeinstablH. Weyer-CzernilofskyU. WunbergT. McConnellD.B. Discovery of novel spiro[3h-indole-3,2′-pyrrolidin]-2(1h)-one compounds as chemically stable and orally active inhibitors of the mdm2-p53 interaction.J. Med. Chem.20165922101471016210.1021/acs.jmedchem.6b00900 27775892
     [Google Scholar]
  56. GollnerA. WeinstablH. FuchsJ.E. RudolphD. GaravelG. HofbauerK.S. Karolyi-OezguerJ. GmaschitzG. HelaW. KerresN. GrondalE. WerniP. RamharterJ. BroekerJ. McConnellD.B. Targeted synthesis of complex spiro[3h-indole-3,2′-pyrrolidin]-2(1h)-ones by intramolecular cyclization of azomethine ylides: Highly potent mdm2-p53 inhibitors.ChemMedChem2019141889310.1002/cmdc.201800617 30458062
     [Google Scholar]
  57. CornillieJ. WozniakA. LiH. GebreyohannesY.K. WellensJ. HompesD. Debiec-RychterM. SciotR. SchöffskiP. Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.Clin. Transl. Oncol.202022454655410.1007/s12094‑019‑02158‑z 31201607
     [Google Scholar]
  58. WenjuanZ. VaubelR.A. OhJ.H. MladekA.C. TaleleS. WenqiuZ. WallerK.L. BurgenskeD.M. SarkariaJ.N. ElmquistW.F. Delivery versus potency in treating brain tumors: Bi-907828, a mdm2-p53 antagonist with limited bbb penetration but significant in vivo efficacy in glioblastoma.Mol. Cancer Ther.2024231475510.1158/1535‑7163.MCT‑23‑0217 37828724
     [Google Scholar]
  59. ArnholdV. SchmelzK. ProbaJ. WinklerA. WünschelJ. ToedlingJ. DeubzerH.E. KünkeleA. EggertA. SchulteJ.H. HundsdoerferP. Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma.Oncotarget2018922304231910.18632/oncotarget.23409 29416773
     [Google Scholar]
  60. da MotaV.H.S. Freire de MeloF. de BritoB.B. SilvaF.A.F. TeixeiraK.N. Molecular docking of DS-3032B, a mouse double minute 2 enzyme antagonist with potential for oncology treatment development.World J. Clin. Oncol.202213649650410.5306/wjco.v13.i6.496 35949428
     [Google Scholar]
  61. SenapatiJ. MuftuogluM. IshizawaJ. AbbasH.A. LoghaviS. BorthakurG. YilmazM. IssaG.C. DaraS.I. BasyalM. LiL. NaqviK. PourebrahimR. JabbourE.J. KornblauS.M. ShortN.J. PemmarajuN. Garcia-ManeroG. RavandiF. KhouryJ. DaverN. KantarjianH.M. AndreeffM. DiNardoC.D. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.Blood Cancer J.202313110110.1038/s41408‑023‑00871‑1 37386016
     [Google Scholar]
  62. EzzatM.A.F. ElmasryG.F. El-MageedM.M.A.A. FouadM.A. Abdel-AzizH.A. ElewaS.I. Design, synthesis, and biological evaluation of furan‐bearing pyrazolo[3,4‐ b]pyridines as novel inhibitors of CDK2 and P53–MDM2 protein–protein interaction.Drug Dev. Res.20238461183120310.1002/ddr.22079 37191966
     [Google Scholar]
  63. DingQ. ZhangZ. LiuJ.J. JiangN. ZhangJ. RossT.M. ChuX.J. BartkovitzD. PodlaskiF. JansonC. TovarC. FilipovicZ.M. HigginsB. GlennK. PackmanK. VassilevL.T. GravesB. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.J. Med. Chem.201356145979598310.1021/jm400487c 23808545
     [Google Scholar]
  64. SkalniakL. KocikJ. PolakJ. SkalniakA. RakM. Wolnicka-GlubiszA. HolakT. Prolonged idasanutlin (rg7388) treatment leads to the generation of p53-mutated cells.Cancers (Basel)2018101139610.3390/cancers10110396 30352966
     [Google Scholar]
  65. FanX. WangY. SongJ. WuH. YangM. LuL. WengX. LiuL. NieG. MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma.Cancer Biol. Ther.201920101328133610.1080/15384047.2019.1638677 31311404
     [Google Scholar]
  66. BerberichA. KesslerT. ThoméC.M. PuschS. HielscherT. SahmF. OezenI. SchmittL.M. CiprutS. HuckeN. RuebmannP. FischerM. LemkeD. BreckwoldtM.O. von DeimlingA. BendszusM. PlattenM. WickW. Targeting resistance against the mdm2 inhibitor rg7388 in glioblastoma cells by the mek inhibitor trametinib.Clin. Cancer Res.201925125326510.1158/1078‑0432.CCR‑18‑1580 30274984
     [Google Scholar]
  67. ChenL. PastorinoF. BerryP. BonnerJ. KirkC. WoodK.M. ThomasH.D. ZhaoY. DagaA. VealG.J. LunecJ. NewellD.R. PonzoniM. TweddleD.A. Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma.Int. J. Cancer2019144123146315910.1002/ijc.32058 30536898
     [Google Scholar]
  68. UyG.L. AssoulineS. YoungA.M. BlotnerS. HigginsB. ChenL.C. YeeK. Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia.Invest. New Drugs20203851430144110.1007/s10637‑020‑00907‑4 32020437
     [Google Scholar]
  69. Abdul RazakA.R. MillerW.H.Jr UyG.L. BlotnerS. YoungA.M. HigginsB. ChenL.C. GoreL. A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.Invest. New Drugs20203841156116510.1007/s10637‑019‑00869‑2 31734832
     [Google Scholar]
  70. DilrubaS. KalaydaG.V. Platinum-based drugs: Past, present and future.Cancer Chemother. Pharmacol.20167761103112410.1007/s00280‑016‑2976‑z 26886018
     [Google Scholar]
  71. LiuW. MaY. HeY. LiuY. GuoZ. HeJ. HanX. HuY. LiM. JiangR. WangS. Discovery of novel p53-mdm2 inhibitor (rg7388)-conjugated platinum(iv) complexes as potent antitumor agents.J. Med. Chem.202467119645966110.1021/acs.jmedchem.4c00784 38776419
     [Google Scholar]
  72. ZhuangC. MiaoZ. ZhuL. DongG. GuoZ. WangS. ZhangY. WuY. YaoJ. ShengC. ZhangW. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.J. Med. Chem.201255229630964210.1021/jm300969t 23046248
     [Google Scholar]
  73. SiD. LuoH. ZhangX. YangK. WenH. LiW. LiuJ. Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors.Bioorg. Chem.202111510526810.1016/j.bioorg.2021.105268 34426149
     [Google Scholar]
  74. RewY. SunD. Gonzalez-Lopez De TurisoF. BartbergerM.D. BeckH.P. CanonJ. ChenA. ChowD. DeignanJ. FoxB.M. GustinD. HuangX. JiangM. JiaoX. JinL. KayserF. KopeckyD.J. LiY. LoM.C. LongA.M. MichelsenK. OlinerJ.D. OsgoodT. RagainsM. SaikiA.Y. SchneiderS. TotevaM. YakowecP. YanX. YeQ. YuD. ZhaoX. ZhouJ. MedinaJ.C. OlsonS.H. Structure-based design of novel inhibitors of the MDM2-p53 interaction.J. Med. Chem.201255114936495410.1021/jm300354j 22524527
     [Google Scholar]
  75. SunD. LiZ. RewY. GribbleM. BartbergerM.D. BeckH.P. CanonJ. ChenA. ChenX. ChowD. DeignanJ. DuquetteJ. EksterowiczJ. FisherB. FoxB.M. FuJ. GonzalezA.Z. Gonzalez-Lopez De TurisoF. HouzeJ.B. HuangX. JiangM. JinL. KayserF. LiuJ.J. LoM.C. LongA.M. LucasB. McGeeL.R. McIntoshJ. MihalicJ. OlinerJ.D. OsgoodT. PetersonM.L. RovetoP. SaikiA.Y. ShafferP. TotevaM. WangY. WangY.C. WortmanS. YakowecP. YanX. YeQ. YuD. YuM. ZhaoX. ZhouJ. ZhuJ. OlsonS.H. MedinaJ.C. Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.J. Med. Chem.20145741454147210.1021/jm401753e 24456472
     [Google Scholar]
  76. WangY. ZhuJ. LiuJ.J. ChenX. MihalicJ. DeignanJ. YuM. SunD. KayserF. McGeeL.R. LoM.C. ChenA. ZhouJ. YeQ. HuangX. LongA.M. YakowecP. OlinerJ.D. OlsonS.H. MedinaJ.C. Optimization beyond AMG 232: Discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein–protein interaction.Bioorg. Med. Chem. Lett.201424163782378510.1016/j.bmcl.2014.06.073 25042256
     [Google Scholar]
  77. MaY. LahueB.R. GibeauC.R. ShippsG.W.Jr BogenS.L. WangY. GuoZ. GuziT.J. Pivotal role of an aliphatic side chain in the development of an hdm2 inhibitor.ACS Med. Chem. Lett.20145557257510.1021/ml500019s 24900882
     [Google Scholar]
  78. KangM.H. ReynoldsC.P. KolbE.A. GorlickR. CarolH. LockR. KeirS.T. MarisJ.M. WuJ. LyalinD. KurmashevaR.T. HoughtonP.J. SmithM.A. Initial testing (stage 1) of mk-8242-a novel mdm2 inhibitor-by the pediatric preclinical testing program.Pediatr. Blood Cancer201663101744175210.1002/pbc.26064 27238606
     [Google Scholar]
  79. ReutershanM.H. MachacekM.R. AltmanM.D. BogenS. CaiM. CammaranoC. ChenD. ChristopherM. CryanJ. DaublainP. FraderaX. GedaP. GoldenblattP. HillA.D. KemperR.A. KutilekV. LiC. MartinezM. McCoyM. NairL. PanW. ThompsonC.F. ScapinG. ShizukaM. SpatzM.L. SteinhuebelD. SunB. VossM.E. WangX. YangL. YehT.C. DussaultI. MarshallC.G. TrotterB.W. Discovery of mk-4688: An efficient inhibitor of the hdm2-p53 protein-protein interaction.J. Med. Chem.20216421162131624110.1021/acs.jmedchem.1c01524 34714078
     [Google Scholar]
  80. GessierF. KallenJ. JacobyE. ChèneP. Stachyra-ValatT. RuetzS. JeayS. HolzerP. MasuyaK. FuretP. Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53–MDM2 interaction with a distinct binding mode.Bioorg. Med. Chem. Lett.201525173621362510.1016/j.bmcl.2015.06.058 26141769
     [Google Scholar]
  81. HolzerP. MasuyaK. FuretP. KallenJ. Valat-StachyraT. FerrettiS. BerghausenJ. Bouisset-LeonardM. BuschmannN. Pissot-SoldermannC. RynnC. RuetzS. StutzS. ChèneP. JeayS. GessierF. Discovery of a dihydroisoquinolinone derivative (nvp-cgm097): A highly potent and selective mdm2 inhibitor undergoing phase 1 clinical trials in p53wt tumors.J. Med. Chem.201558166348635810.1021/acs.jmedchem.5b00810 26181851
     [Google Scholar]
  82. BauerS. DemetriG.D. HalilovicE. DummerR. MeilleC. TanD.S.W. GuerreiroN. JullionA. FerrettiS. JeayS. Van BreeL. Hourcade-PotelleretF. WuerthnerJ.U. FabreC. CassierP.A. Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies.Br. J. Cancer2021125568769810.1038/s41416‑021‑01444‑4 34140638
     [Google Scholar]
  83. FuretP. MasuyaK. KallenJ. Stachyra-ValatT. RuetzS. GuagnanoV. HolzerP. MahR. StutzS. VaupelA. ChèneP. JeayS. SchlapbachA. Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument.Bioorg. Med. Chem. Lett.201626194837484110.1016/j.bmcl.2016.08.010 27542305
     [Google Scholar]
  84. LiaoG. YangD. MaL. LiW. HuL. ZengL. WuP. DuanL. LiuZ. The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy.Eur. J. Med. Chem.20181591910.1016/j.ejmech.2018.09.044 30253242
     [Google Scholar]
  85. SteinE.M. DeAngeloD.J. ChromikJ. ChatterjeeM. BauerS. LinC.C. SuarezC. de VosF. SteeghsN. CassierP.A. TaiD. KiladjianJ.J. YamamotoN. MousR. EsteveJ. MinamiH. FerrettiS. GuerreiroN. MeilleC. RadhakrishnanR. PereiraB. MaricontiL. HalilovicE. FabreC. CarpioC. Results from a first-in-human phase i study of siremadlin (hdm201) in patients with advanced wild-type tp53 solid tumors and acute leukemia.Clin. Cancer Res.202228587088110.1158/1078‑0432.CCR‑21‑1295 34862243
     [Google Scholar]
  86. MiyazakiM. KawatoH. NaitoH. IkedaM. MiyazakiM. KitagawaM. SekiT. FukutakeS. AonumaM. SogaT. Discovery of novel dihydroimidazothiazole derivatives as p53–MDM2 protein–protein interaction inhibitors: Synthesis, biological evaluation and structure–activity relationships.Bioorg. Med. Chem. Lett.201222206338634210.1016/j.bmcl.2012.08.086 22995624
     [Google Scholar]
  87. MiyazakiM. NaitoH. SugimotoY. KawatoH. OkayamaT. ShimizuH. MasayaM. KitagawaM. SekiT. FukutakeS. AonumaM. SogaT. Lead optimization of novel p53-MDM2 interaction inhibitors possessing dihydroimidazothiazole scaffold.Bioorg. Med. Chem. Lett.201323372873210.1016/j.bmcl.2012.11.091 23266121
     [Google Scholar]
  88. MiyazakiM. NaitoH. SugimotoY. YoshidaK. KawatoH. OkayamaT. ShimizuH. MiyazakiM. KitagawaM. SekiT. FukutakeS. ShioseY. AonumaM. SogaT. Synthesis and evaluation of novel orally active p53–MDM2 interaction inhibitors.Bioorg. Med. Chem.201321144319433110.1016/j.bmc.2013.04.056 23685175
     [Google Scholar]
  89. MiyazakiM. UotoK. SugimotoY. NaitoH. YoshidaK. OkayamaT. KawatoH. MiyazakiM. KitagawaM. SekiT. FukutakeS. AonumaM. SogaT. Discovery of DS-5272 as a promising candidate: A potent and orally active p53–MDM2 interaction inhibitor.Bioorg. Med. Chem.201523102360236710.1016/j.bmc.2015.03.069 25882531
     [Google Scholar]
  90. TuX. LiL. ZhangH.B. LiuY. XiaoZ.X. CaoY. Identification of a novel MDM2-p53 interaction inhibitor using virtual screening and docking strategy.Journal of Sichuan University2019562369376
     [Google Scholar]
  91. ZhangS. YanZ. LiY. GongY. LyuX. LouJ. ZhangD. MengX. ZhaoY. Structure-based discovery of mdm2/4 dual inhibitors that exert antitumor activities against mdm4-overexpressing cancer cells.J. Med. Chem.20226586207623010.1021/acs.jmedchem.2c00095 35420431
     [Google Scholar]
  92. ChengJ. YanZ. JiangK. LiuC. XuD. LyuX. HuX. ZhangS. ZhouY. LiJ. ZhaoY. Discovery of jn122, a spiroindoline-containing molecule that inhibits mdm2/p53 protein-protein interaction and exerts robust in vivo antitumor efficacy.J. Med. Chem.20236624169911702510.1021/acs.jmedchem.3c01815 38062557
     [Google Scholar]
  93. KonoplevaM. MartinelliG. DaverN. PapayannidisC. WeiA. HigginsB. OttM. MascarenhasJ. AndreeffM. MDM2 inhibition: An important step forward in cancer therapy.Leukemia202034112858287410.1038/s41375‑020‑0949‑z 32651541
     [Google Scholar]
  94. WangW. AlbadariN. DuY. FowlerJ.F. SangH.T. XianW. McKeonF. LiW. ZhouJ. ZhangR. Mdm2 inhibitors for cancer therapy: The past, present, and future.Pharmacol. Rev.202476341445310.1124/pharmrev.123.001026 38697854
     [Google Scholar]
  95. ManfrediJ.J. Mdm2 and mdmx: Partners in p53 destruction.Cancer Res.20218171633163410.1158/0008‑5472.CAN‑21‑0145 34003788
     [Google Scholar]
  96. WadeM. LiY.C. WahlG.M. MDM2, MDMX and p53 in oncogenesis and cancer therapy.Nat. Rev. Cancer2013132839610.1038/nrc3430 23303139
     [Google Scholar]
  97. LiJ. ZhangS. GaoL. ChenY. XieX. A cell-based high-throughput assay for the screening of small-molecule inhibitors of p53-MDM2 interaction.SLAS Discov.201116445045610.1177/1087057111399191 21471462
     [Google Scholar]
  98. YurlovaL. DerksM. BuchfellnerA. HicksonI. JanssenM. MorrisonD. StansfieldI. BrownC.J. GhadessyF.J. LaneD.P. RothbauerU. ZolghadrK. KrauszE. The fluorescent two-hybrid assay to screen for protein-protein interaction inhibitors in live cells: Targeting the interaction of p53 with Mdm2 and Mdm4.SLAS Discov.201419451652510.1177/1087057113518067 24476585
     [Google Scholar]
  99. SomaiahN. TapW. MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action.Cancer Treat. Rev.202412210266810.1016/j.ctrv.2023.102668 38104352
     [Google Scholar]
  100. BhatiaN. KhatorR. KulkarniS. SinghY. KumarP. TharejaS. Recent advancements in the discovery of mdm2/mdm2-p53 interaction inhibitors for the treatment of cancer.Curr. Med. Chem.202330323668370110.2174/0929867330666221114103924 37190755
     [Google Scholar]
/content/journals/acamc/10.2174/0118715206358340250121060830
Loading
Research Progress on Small Molecule Inhibitors of MDM2-p53 Protein-protein Interaction
Anti-Cancer Agents in Medicinal Chemistry 26, 147 (2026); https://doi.org/10.2174/0118715206358340250121060830
/content/journals/acamc/10.2174/0118715206358340250121060830
/content/journals/acamc/10.2174/0118715206358340250121060830
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): anti-cancer agents; MDM2; p53; small-molecule inhibitors; targeted therapy; tumor suppressor protein

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test